73
Views
13
CrossRef citations to date
0
Altmetric
Hypothesis

Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study

, , , , , & show all
Pages 113-118 | Published online: 11 Jan 2018

Abstract

Purpose

Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly and can cause irreversible blindness and aortitis. Varicella zoster (VZ), which is potentially preventable by vaccination, has been proposed as a possible immune trigger for GCA, but this is controversial. The incidence of GCA varies widely by country. If VZ virus contributes to the immunopathogenesis of GCA we hypothesized that nations with increased incidence of GCA would also have increased incidence of herpes zoster (HZ). We conducted an ecologic analysis to determine the relationship between the incidence of HZ and GCA in different countries.

Methods

A literature search for the incidence rates (IRs) of GCA and HZ from different countries was conducted. Correlation and linear regression was performed comparing the disease IR of each country for subjects 50 years of age or older.

Results

We found the IR for GCA and HZ from 14 countries. Comparing the IRs for GCA and HZ in 50-year-olds, the Pearson product-moment correlation (r) was −0.51, with linear regression coefficient (β) −2.92 (95% CI −5.41, −0.43; p=0.025) using robust standard errors. Comparing the IRs for GCA and HZ in 70-year-olds, r was −0.40, with β −1.78, which was not statistically significant (95% CI −4.10, 0.53; p=0.12).

Conclusion

Although this geo-epidemiologic study has potential for aggregation and selection biases, there was no positive biologic gradient between the incidence of clinically evident HZ and GCA.

Introduction

Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly and can cause irreversible blindness, myocardial infarction, aortic aneurysm, stroke and rarely death.Citation1 The incidence of GCA is projected to increase as our population ages, with predicted cost of $76 billion in the United States alone, by the year 2050.Citation2

Gilden et al and Nagel et al found varicella zoster virus (VZV) in the temporal arteries of 73% of patients with biopsy-proven GCA and propose VZV as a possible trigger in the immunopathogenesis of GCA.Citation3,Citation4 Although this potential role of VZV in the development of GCA has not been substantiated by other investigators, and remains controversial, Gilden suggested adjunctive antivirals be considered in the treatment of GCA.Citation5

The incidence rate (IR) of GCA varies widely by country, being the highest in northern Europe and lowest in Asia.Citation2,Citation6 We hypothesized that if VZV contributed to GCA, the GCA IRs per 100,000 subjects, 50 years of age or older (IRGCA) per country should correlate with the local herpes zoster IRs (IRHZ). To test this hypothesis, we performed a regression analysis using the published IRGCA and IRHZ from different countries.

Methods

The IRGCA was searched for on PubMed, Embase, and Google Scholar from inception to July 1, 2017 using the search terms: incidence, epidemiology, country, temporal arteritis and GCA. The same search was repeated using herpes zoster and shingles in place of the arteritis terms.

The country specific IRs for subjects 50 years of age and older were recorded per 100,000 population for GCA, and per 1,000 person-years for HZ. If IRs were provided for multiple years, the results were averaged ().

Table 1 Incidence rates of giant cell arteritis and herpes zoster per country

The IRGCA in Japan was calculated using Koboyashi’s reported prevalence rate of 1.47 per 100,000 in subjects aged 50 years or older, with average age of onset of 71.5 years.Citation7 Lifespan is thought not to be affected by GCA unless the patient has aortic aneurysm or dissection.Citation8 The average life expectancy in Japan is 83.3 years.Citation9 As GCA is a rare disease and recurrent, the IR was estimated as the prevalence rate/duration of disease =1.3 per million subjects 50 years or older.

Since the peak onset of GCA is in the 8th decade,Citation10 we also examined the IR of HZ in 70 year-olds. If the age brackets straddled our chosen age cut-offs, the IR values from the two adjacent brackets were averaged.

Only countries/regions that had IRs available for both GCA and HZ were used for analysis. Paired t-test was used to examine the time difference in year of publication between the GCA and HZ studies for each country. There was inadequate information in the GCA articles to consistently calculate the within-study standard errors needed for meta-regression. Pearson product-moment correlation coefficients, and linear regression with and without robust standard errors was performed. White’s test was used to test for heteroscedasticity. All statistical tests were conducted with Stata 14.2 (StataCorp LP, College Station, TX, USA), and a two-sided p<0.05 was considered statistically significant.

Results

The IRs for both GCA and HZ were available for 14 countries (), and plotted on . With the exception of Olmsted County and the United Kingdom, the availability of IRGCA and IRHZ from the same time frame and corresponding geographic region was limited. Eight of the 14 countries (57%) in were overlapping in the time frame of the corresponding GCA and HZ studies. On paired t-test, the GCA studies were published on average 4.5 years before the HZ studies (p=0.09). A published IRGCA for Iceland was available. The IRHZ for Iceland was only available for the 60-year age group only (4.7 per 1,000), but not the 50-year-old or 70-year-old age groups, and as such was not used.

Figure 1 Incidence of giant cell arteritis versus incidence of herpes zoster per country.

Notes: Each dot represents a country’s intersecting incidence rates for giant cell arteritis in subjects 50 years or older, and herpes zoster in 50 year-old subjects. The negative sloping red line is the line of best linear fit using the least squares method.
Figure 1 Incidence of giant cell arteritis versus incidence of herpes zoster per country.

Pearson product-moment correlation coefficient (r) comparing IRGCA with: IRHZ in 50 year-olds was −0.51 (p=0.07), and IRHZ in 70-year-olds was −0.40 (p=0.16). Linear regression with robust standard errors showed a regression coefficient (β) −2.92 (95% CI −5.41, −0.43; p=0.025) between the IRGCA $50-year-olds, and the IRHZ in 50-year-olds. For the IRHZ in 70-year-olds, no statistically significant linear dependence of the mean IRGCA on IRHZ was detected (β=−1.78, 95% CI −4.10, 0.53; p=0.12). White’s test did not suggest heteroscedasticity ().

Table 2 Correlation and linear regression of the incidence rates of giant cell arteritis versus herpes zoster

This ecologic study does not support a positive biologic gradient between the IRHZ and IRGCA. Subgroup regression analyses of the per country IRGCA and IRHZ, with and without overlapping timeframes were not statistically significant and did not show a positive regression coefficient.

Discussion

Infections can predispose to systemic vasculitis by mechanisms such as molecular mimicry, epitope spreading, immune response to subdominant epitopes normally hidden from T-cell recognition, or bystander activation.Citation11 If there is a causal relationship between HZ and GCA it is important to define since HZ can be potentially prevented with the shingles vaccine, and because the treatment of GCA might benefit from adjunctive antivirals.

VZV and GCA have some overlapping features. Dendritic cells are thought to play a central role in VZV infection and the immunopathogenesis of GCA.Citation12Citation14 HZ ophthalmicus or multifocal VZV vasculopathy with temporal artery infection may mimic the presentation of GCA. Varicella zoster vasculopathy and GCA can both cause optic neuropathy, cranial nerve palsy, and stroke.

Temporal artery biopsy studies have shown conflicting results on the association of VZV and GCA. Gilden et al and Nagel et al suggested that VZV triggers the immunopathology of GCA, and found increase of 74% VZV in temporal artery biopsy specimens from patients with GCA.Citation3Citation5,Citation15 However, with the exception of Mitchell and Font,Citation16 other investigators have not found substantial VZV in the arterial specimens of biopsy-proven GCA or clinically diagnosed GCA.Citation17Citation22 False positive immunohistochemistry from antibody cross-reactivity to shared epitopes between VZV proteins and arterial smooth muscle elements suggest caution when interpreting pathology findings.Citation23 Gilden and Nagel acknowledge that “the presence of VZV in about 20% of temporal artery biopsies from non-GCA post-mortem controls also suggests that VZV alone is not sufficient to produce disease”.Citation5

A population-based cohort study did not find an increased risk of HZ in patients with GCA compared to non-GCA subjects, even during the first 6 months after glucocorticoid initiation, when patients are on the highest doses.Citation24 A large nested case control study determined that HZ had a modest incidence rate ratio of 1.17 in association with incident GCA.Citation25 A review of two large administrative databases found a two-fold increased risk of GCA with complicated HZ.Citation26

Our ecologic study did not show a positive biologic gradient between the IRHZ and IRGCA. Limitations of this study include possible ecologic fallacy, time, location and/or selection biases, the limited availability of IRGCA and IRHZ, and variable trends in IR. By and large the IRHZ are increasing.Citation27 Zoster sine herpete and asymptomatic VZV infection may have affected our analysis. The IRGCA may be increasing,Citation2 decreasing,Citation6 or cyclical.Citation28 Furthermore, the IRGCA are higher when cases of clinically diagnosed GCA are included with biopsy-proven GCA. It is unlikely that the IRHZ in were significantly affected by zoster vaccination. The Oka/Merck zoster vaccine decreases the risk of shingles by only 51%,Citation29 and was approved for use in the United States and European Union in 2006,Citation30,Citation31 and in Canada in 2008.Citation32 The Olmsted county HZ study published in 2016 reviewed two sets of patients, the latest of which were from 1980 to 2007. In the United States a 5% random sample of Medicare seniors were first offered zoster vaccine in 2007, and uptake was low at 3.9%.Citation33 The first two European countries to recommend nation-wide zoster vaccination for seniors 65 to 74 years of age were the United Kingdom and France in 2013.Citation34 The Australian and Ontario, Canada immunization programs for seniors began in 2016.Citation35,Citation36

Conclusion

The discordant IRs for HZ and GCA question the biologic plausibility of clinically overt HZ as the sole immunopathogenic trigger for GCA. Geo-epidemiology may help elucidate the relationship between VZV and GCA, but more widely available, accurate and updated IRs from different countries are required.

Disclosure

The authors report no conflicts of interest in this work.

References

  • LieJAortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentationSemin Arthritis Rheum19952464224317667646
  • De SmitEPalmerAJHewittAWProjected worldwide disease burden from giant cell arteritis by 2050J Rheumatol201542111912525362658
  • GildenDWhiteTKhmelevaNPrevalence and distribution of VZV in temporal arteries of patients with giant cell arteritisNeurology201584191948195525695965
  • NagelMAWhiteTKhmelevaNAnalysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritisJAMA Neurol201572111281128726349037
  • GildenDNagelMAVaricella zoster virus and giant cell arteritisCurr Opin Infect Dis201629327527926871403
  • MahrAAoubaARichebéPGonzalez-ChiappeSÉpidémiologie et histoire naturelle de l’artérite à cellules géantes (Horton). [Epidemiology and natural history of giant cell arteritis]Rev Med Interne20173810663669 French28457683
  • KobayashiSYanoTMatsumotoYClinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide surveyArthritis Rheum200349459459812910568
  • KermaniTAKennethJWarringtonKJLarge-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosisAnn Rheum Dis201372121989199423253927
  • United NationsWorld population prospects: The 2015 revision, volume I, comprehensive tablesNew York2015 ST/ESA/SER.A/379. Available from: https://esa.un.org/unpd/wpp/publications/Files/WPP2015_Volume-I_Comprehensive-Tables.pdfAccessed August 01, 2017
  • Gonzalez-GayMAVazquez-RodriguezTRLopez-DiazMJMiranda-FilloyJAGonzalez-JuanateyCMartinJLlorcaJEpidemiology of giant cell arteritis and polymyalgia rheumaticaArthritis Rheum200961101454146119790127
  • MoiseevSNovikovPSmitienkoIShchegolevaEGiant cell arteritis, infections and biologicsAnn Rheum Dis2017769e2928057665
  • CicciaFRizzoAFerranteANew insights into the pathogenesis of giant cell arteritisAutoimmun Rev201716767568328479485
  • SamsonMCorbera-BellaltaMAudiaSPlanas-RigolEMartinLCidMCBonnotteBRecent advances in our understanding of giant cell arteritis pathogenesisAutoimmun Rev201716883384428564617
  • SchönrichGRafteryMJDendritic cells as Achilles’ heel and Trojan horse during varicella zoster virus infectionFront Microbiol2015641726005438
  • GildenDWhiteTKhmelevaNKatzBJNagelMABlinded search for varicella zoster virus in giant cell arteritis (GCA)-positive and GCA-negative temporal arteriesJ Neurol Sci201636414114327084233
  • MitchellBMFontRLDetection of varicella zoster virus DNA in some patients with giant cell arteritisInvest Opthalmol Vis Sci2001421125722577
  • MuratoreFCrociSTamagniniINo detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritisSemin Arthritis Rheum201747223524028274481
  • KennedyPGGrinfeldEEsiriMMAbsence of detection of varicella-zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritisJ Neurol Sci20032151–2272914568124
  • Helweg-LarsenJTarpBObelNBaslundBNo evidence of parvovirus B19, chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritisRheumatology (Oxford)200241444544911961176
  • Rodriguez-PlaABosch-GilJAEchevarria-MayoJENo detection of parvovirus B19 or herpesvirus DNA in giant cell arteritisJ Clin Virol2004311111515288607
  • Álvarez-LafuenteRFernández-GutiérrezBJoverJAHuman parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reactionAnn Rheum Dis200564578078215834059
  • NordborgCNordborgEPetursdottirVLaGuardiaJMahalingamRWellishMGildenDHSearch for varicella zoster virus in giant cell arteritisAnn Neurol19984434134149749614
  • PisapiaDJLaviEVZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivityExp Mol Pathol2016100111411526688577
  • SchäferVSKermaniTACrowsonCSIncidence of herpes zoster in patients with giant cell arteritis: a population-based cohort studyRheumatology (Oxford)201049112104210820627970
  • RheeRLGraysonPCMerkelPATomassonGInfections and the risk of incident giant cell arteritis: a population-based, case-control studyAnn Rheum Dis20177661031103527895041
  • EnglandBRMikulsTRXieFYangSChenLCurtisJHerpes zoster and the risk of incident giant cell arteritisArthritis Rheumatol201769122351235828853238
  • KawaiKGebremeskelGAcostaCJSystematic review of incidence and complications of herpes zoster: towards a global perspectiveBMJ Open201446e004833
  • WingSRiderLGJohnsonJRMillerFWMattesonELCrowsonCSGabrielSEDo solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?BMJ Open2015155e006636
  • OxmanMNLevinMJJohnsonGRA vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsN Engl J Med2005352222271228415930418
  • Centers for Disease Control and PreventionWhat everyone should know about shingles vaccineCDC2016 Available from: https://www.cdc.gov/vaccines/vpd/shingles/public/index.htmlAccessed December 8, 2017
  • European Medicines AgencyZostavax European public assessment reportEuropean Medicines Agency (EMEA)2006 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000674/WC500053457.pdfAccessed December 8, 2017
  • newswire.ca [homepage on the Internet]ZOSTAVAX(TM) approved in Canada – The first and only vaccine for the prevention of shinglesCISION News Wire2008 Available from: http://www.newswire.ca/news-releases/zostavaxtm-approved-in-canada---the-first-and-only-vaccine-for-the-prevention-of-shingles-536564411.htmlAccessed December 8, 2017
  • LanganSMSmeethLMargolisDJThomasSLHerpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort studyPLoS Med2013104e100142023585738
  • NHS EnglandEnhanced service specification Shingles (catch-up) vaccination programme 2014NHS England gateway reference: 01773 Available from: https://www.england.nhs.uk/wp-content/uploads/2014/06/shingles-serv-spec.pdfAccessed August 01, 2017
  • immunise.health.gov.au [homepage on the Internet]Immunise Australia ProgramAustralian Government Department of Health2016 Available from: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/IT0213.cntAccessed December 8, 2017
  • news.ontario.ca [homepage on the Internet]Ontario making shingles vaccine free for seniorsGovernment of Ontario2016 Available from: https://news.ontario.ca/mohltc/en/2016/09/ontario-making-shingles-vaccine-free-for-seniors.htmlAccessed December 8, 2017
  • DiamantopoulosAMyklebustGWigaardEAmundsenLSoldalDMHaugebergGThe incidence rate of giant cell arteritis in southern Norway is lower than previously reported: A result of temporal variations or a sign of a true shift in incidence rates?Paper presented at: EULAR 2014: Scientific AbstractsJune 13; 2014Paris, France
  • RimselieneGVainioKGiboryMSalamancaBVFlemEVaricella-zoster virus susceptibility and primary healthcare consultations in NorwayBMC Infect Dis20161625427266273
  • FranzénPSutinenSvon KnorringJGiant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988J Rheumatol19921922732761629827
  • KarhunenMLeinoTSaloHDavidkinIKilpiTAuranenKModelling the impact of varicella vaccination on varicella and zosterEpidemiol Infect2010138446948119796447
  • MohammadAJNilssonJJacobssonLTMerkelPATuressonCIncidence and mortality rates of biopsy-proven giant cell arteritis in southern SwedenAnn Rheum Dis201574699399724442881
  • StudahlMPetzoldMCasselTDisease burden of herpes zoster in Sweden – predominance in the elderly and in women – a register based studyBMC Infect Dis20131358624330510
  • SmeethLCookCHallAJIncidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001Ann Rheum Dis20066581093109816414971
  • BrissonMEdmundsWJEpidemiology of varicella-zoster virus in England and WalesJ Med Virol200370Suppl 1S9S1412627480
  • ChandranAKUdayakumarPDCrowsonCSWarringtonKJMattesonELThe incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009Scand J Rheumatol201544321521825606666
  • KawaiKYawnBPWollanPHarpazRIncreasing incidence of herpes zoster over a 60-year period from a population-based studyClin Infect Dis201663222122627161774
  • Gonzalez-GayMAMiranda-FilloyJALopez-DiazMJGiant cell arteritis in northwestern Spain: A 25-year epidemiologic studyMedicine (Baltimore)2007862616817435586
  • Morant-TalamanteNDiez-DomingoJMartínez-ÚbedaSPuig-BarberáJAlemán-SánchezSPérez-BrevaLHerpes zoster surveillance using electronic databases in the Valencian Community (Spain)BMC Infect Dis20131346324094135
  • Abdul-RahmanAMMoltenoACBBevinTHThe epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysisN Z Med J201112413294452
  • ReidJSAh WongBHerpes zoster (shingles) at a large New Zealand general practice: incidence over 5 yearsN Z Med J201412714075660
  • Bas-LandoMBreuerGSBerkunYMatesMSonnenblickMNesherGThe incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuationsClin Exp Rheumatol2007251 Suppl 44S15S1717428357
  • WeitzmanDShavitOSteinMCohenRChodickGShalevVA population based study of the epidemiology of herpes zoster and its complicationsJ Infect201367546346923872209
  • RamsteadCLPatelADGiant cell arteritis in a neuro-ophthalmology clinic in Saskatoon, 1998–2003Can J Ophthalmol200742229529817392855
  • TanuseputroPZagorskiBChanKJKwongJCPopulation-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination programVaccine201129478580858421939721
  • BarrierJPionPMassariRPeltierPRojouanJGrolleauJYApproche epidemiologique de la maladie de Horton dans le departement de Loire-Atlantique 110 cas en 10 ans (1970–1979). [Epidemiologic approach to Horton’s disease in the department of Loire-Atlantique. 110 cases in 10 years (1970–1979)]Rev Med Interne1982311320 French7100693
  • Gonzalez ChiappeSSarazinMTurbelinCHerpes zoster: Burden of disease in FranceVaccine201028507933793820946861
  • CatanosoMMacchioniPBoiardiLIncidence, prevalence, and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year periodArthritis Care Res (Hoboken)201769343043827214746
  • GialloretiLEMeritoMPezzottiPEpidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based studyBMC Infect Dis20101023020682044
  • DunstanELesterSLRischmuellerMEpidemiology of biopsy-proven giant cell arteritis in South AustraliaIntern Med J2014441323924118799
  • SteinANBrittHHarrisonCConwayELCunninghamAMacintyreCRHerpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and olderVaccine200927452052919027048
  • Reinhold-KellerEHerlynKWagner-BastmeyerRGrossWLStable incidence of primary systemic vasculitides over five years: Results from the German vasculitis registerArthritis Rheum2005531939915696553
  • UltschBSiedlerARieckTReinholdTKrauseGWichmannOHerpes zoster in Germany: quantifying the burden of diseaseBMC Infect Dis20111117321679419
  • ToyamaNShirakiKSociety of the Miyazaki Prefecture DermatologistsEpidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefectureJ Med Virol200981122053205819856466